Description

9Alpha,11Alpha-Dihydroxy-15,15-Difluoro-16-Phenoxy-17,18,19,20-Tetranor-Prosta-5Z,13E-Dien-1-Oic Acid is a high-value, advanced prostaglandin derivative, specifically engineered with fluorine substitutions to enhance its metabolic stability and receptor binding affinity. This compound is critical for pharmaceutical research and development, serving as a key synthetic intermediate or active pharmaceutical ingredient (API) in the creation of novel therapeutics. It is primarily sought by pharmaceutical companies and advanced research institutions focused on developing treatments for ophthalmic conditions, cardiovascular diseases, and other disorders mediated by prostaglandin pathways. Our supply is characterized by stringent quality control, ensuring the purity and consistency required for sensitive preclinical and clinical applications.

Application

• Pharmaceutical Intermediate: A crucial building block in the multi-step synthesis of potent prostaglandin analog APIs.
• Ophthalmic Drug Development: Research and production of next-generation medications for glaucoma and ocular hypertension.
• Cardiovascular Research: Investigation of vascular tone regulation and the development of related therapeutic agents.
• Biochemical Research: Used as a high-purity reference standard and probe in prostaglandin receptor (FP, EP) studies.
• Process Development & Scale-Up: Supports process chemistry teams in optimizing synthetic routes from lab to pilot and commercial scale.
• Contract Manufacturing (CMO): Supplied to CMOs engaged in the production of prostaglandin-based drugs under cGMP guidelines.

Basic Information

Product Name	9Alpha,11Alpha-Dihydroxy-15,15-Difluoro-16-Phenoxy-17,18,19,20-Tetranor-Prosta-5Z,13E-Dien-1-Oic Acid
CAS No.	209860-88-8
Molecular Formula	C26H32F2O5
Molecular Weight	462.53 g/mol
Synonyms	15,15-Difluoro-16-phenoxy-17,18,19,20-tetranor-PGF2α; 9α,11α-Dihydroxy-15,15-difluoro-16-phenoxy-tetranor-prosta-5Z,13E-dien-1-oic Acid; Fluprostenol Impurity; Prostaglandin F2α (15,15-difluoro, 16-phenoxy) analog; AGN 191976; PGF2α fluoro phenoxy derivative; Travoprost Related Compound
EINECS	Contact for details

Quality Control

Every batch of 9Alpha,11Alpha-Dihydroxy-15,15-Difluoro-16-Phenoxy-17,18,19,20-Tetranor-Prosta-5Z,13E-Dien-1-Oic Acid is manufactured and tested under a strict quality management system. We provide comprehensive analytical data to support its use in regulated environments. Standard testing includes identification (IR, NMR), assay (HPLC), and control of specified impurities. A detailed Certificate of Analysis (COA) is supplied with each shipment, documenting compliance with agreed specifications. Our quality systems are designed to meet the expectations of cGMP, ISO, and other relevant pharmaceutical guidelines.

Storage

Preserve in a tightly closed container, protected from light. Store at controlled room temperature (15-25°C) or as specified on the label or COA. This product is hygroscopic (moisture-sensitive) and must be kept in a dry environment. For long-term storage, consider desiccants or inert atmosphere to maintain stability.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0%
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.1%
Related Substances (HPLC)	Individual impurity: ≤ 0.5% Total impurities: ≤ 2.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.